0001662579-23-000095.txt : 20230919 0001662579-23-000095.hdr.sgml : 20230919 20230919192009 ACCESSION NUMBER: 0001662579-23-000095 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230918 FILED AS OF DATE: 20230919 DATE AS OF CHANGE: 20230919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Adams Kendra CENTRAL INDEX KEY: 0001991929 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39567 FILM NUMBER: 231265059 MAIL ADDRESS: STREET 1: C4 THERAPEUTICS, INC. STREET 2: 490 ARSENAL WAY, SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: C4 Therapeutics, Inc. CENTRAL INDEX KEY: 0001662579 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 475617627 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (617) 231-0700 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 3 1 wk-form3_1695165599.xml FORM 3 X0206 3 2023-09-18 0 0001662579 C4 Therapeutics, Inc. CCCC 0001991929 Adams Kendra C/O C4 THERAPEUTICS, INC. 490 ARSENAL WAY #120 WATERTOWN MA 02472 0 1 0 0 Chief Financial Officer Common Stock 21640 D Stock Option (Right to Buy) 19 2030-11-08 Common Stock 57375 D Stock Option (Right to Buy) 22.71 2032-02-13 Common Stock 45000 D Stock Option (Right to Buy) 5.67 2033-02-12 Common Stock 75000 D Performance Restricted Stock Units 2025-02-28 Common Stock 16500 D Includes a grant of 15,000 restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs vest in four equal annual installments, with the first installment vesting on February 13, 2024, subject to the Reporting Person's continued service on each vesting date. Represents underlying unexercised stock options that were granted on November 9, 2020. The terms of the original grant provide that 25% of this option vested and became exercisable on November 9, 2021, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each vesting date. This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 14, 2022, subject to the Reporting Person's continued service on each vesting date. This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 13, 2023, subject to the Reporting Person's continued service on each vesting date. Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Exhibit 24 - Power of Attorney /s/ Jolie M. Siegel, Attorney-in-Fact 2023-09-19 EX-24 2 adams.txt EX-24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Jolie M. Siegel, Shagha T. Russell, Andrew J. Hirsch, Shoaib Ghias and Nathan Needle, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of C4 Therapeutics, Inc. (the "Company"), (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the United States Securities and Exchange Commission using the EDGAR System, (ii) Forms 3, 4 and 5, (iii) Schedule 13D, (iv) Schedule 13G and (v) amendments of each thereof, in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D, Schedule 13G or any amendments thereto and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in- fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorney-in-fact. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney may be filed with the United States Securities and Exchange Commission as a confirming statement of the authority granted herein. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of September 18, 2023. /s/ Kendra Adams --------------------------------- Name: Kendra Adams